Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul 27:4:152.
doi: 10.1186/1756-3305-4-152.

Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria

William R Brieger  1 , Joseph C Okeibunor, Adenike O Abiose, Samuel Wanji, Elizabeth Elhassan, Richard Ndyomugyenyi, Uche V Amazigo
Affiliations

Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria

William R Brieger et al. Parasit Vectors. .

Abstract

Background: As the African Programme for Onchocerciasis Control (APOC) matured into its 10th year of ensuring community involvement in mass annual treatment of onchocerciasis with ivermectin, there was recognition of a need to study not only annual coverage of ivermectin in villages but also the compliance of individual villagers with these annual treatments. This was based on the concern that while population coverage goals may be achieved each year, there might be segments of the population who systematically are not complying with the annual regimen, thus creating a reservoir of infection and threatening program gains.

Methods: A multi-site study in five APOC sponsored projects in Nigeria and Cameroon was undertaken to identify the socio-demographic correlates of compliance with ivermectin treatment. A total of 8,480 villagers above 9 years of age selected through a systematic random sampling from 101 communities were surveyed to ascertain their levels of compliance, by adapting APOC's standard household ivermectin survey form. Community leaders, community directed distributors (CDDs) of ivermectin and health workers were interviewed with in-depth interview guides, while focus group discussions were held with community members to help explain how socio-demographic factors might affect compliance.

Results: Eight-year compliance ranged from 0 to 8 times with 42.9% taking ivermectin between 6-8 times annually (high compliance). In bivariate analysis high compliance was positively associated with being male, over 24 years of age, having been married, not being Christian, having little or no formal education and being in the ethnic majority. These variables were also confirmed through regression analysis based on total times ivermectin was taken over the period. While these factors explained only 8% of the overall variation in compliance, ethnic status and education appeared to be the strongest factors. Those with higher education may be more mobile and harder to reach while neglect of ethnic minorities has also been documented in other programs.

Conclusion: These findings can help managers of CDTI programmes to ensure ivermectin reaches all segments of the population equally.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CDTI Compliance Rates.
See this image and copyright information in PMC

References

    1. Amazigo U, Boatin B. The future of onchocerciasis control in Africa. The Lancet. 2006;368:1946–1947. doi: 10.1016/S0140-6736(06)69786-9. - DOI - PubMed
    1. Plaisier AP, Alley ES, van Oortmarssen GJ, Boatin BA, Habbema JDF. Required duration of combined annual ivermectin treatment and vector control in the Onchocerciasis Control programme in West Africa. Bulletin of the World Health Organization. 1997;75(3):237–245. - PMC - PubMed
    1. Borsboom GJ, Boatin BA, Nagelkerke NJ, Agoua H, Akpoboua KL, Alley EW, Bissan Y, Renz A, Yameogo L, Remme JH, Habbema JD. Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Filaria J. 2003;2(1):8. doi: 10.1186/1475-2883-2-8. - DOI - PMC - PubMed
    1. Tielsch JM, Beeche A. Impact of ivermectin on illness and disability associated with onchocerciasis. Trop Med Int Health. 2004;9(4):A45–A56. doi: 10.1111/j.1365-3156.2004.01213.x. - DOI - PubMed
    1. Amazigo U, Okeibunor JC, Matovu V, Zouré H, Bump J, Seketeli A. Performance versus predictors: Evaluating sustainability in community-directed treatment projects of the African Programme for Onchocerciasis Control. Soc Sci Med. 2007;64(2007):2070–2082. - PubMed

Publication types